Industry news that matters to you.  Learn more

Metamark Genetics and HistoRX Announce Licensing Agreement for AQUA Technology

Metamark Genetics, Inc., a privately held molecular diagnostics company focused on oncology, and HistoRx, Inc., a tissue-based diagnostics company, yesterday announced a multi-year licensing agreement. Metamark has been granted a worldwide license to the AQUA technology by HistoRx for the clinical commercialization of Metamark’s proprietary MetamarkDx Prognostic Assays.

Aushon BioSystems and LightArray Partner to Offer Protein Biomarker Testing Services and Products in China

Aushon BioSystems, Inc., a leading provider of multiplex immunoassay products and services for biomarker discovery, development and analysis announced during the ChinaTrials 2010 Summit in Beijing, China, that it has entered into a partnership with LightArray Biotech Company, Ltd., to provide Aushon’s comprehensive suite of multiplex biomarker products and services to pharmaceutical, biotechnical, and academic research institutions located in mainland China.

Added Complexities for Biomarkers

For metastatic colorectal cancer, there has been increasing recognition that certain molecular changes in the genes of the tumor (often called biomarkers) can help predict the benefit from certain chemotherapies like cetuximab.

One of the most frequently used biomarkers is the KRAS mutation, which predicts lack of efficacy to cetuximab and panitumumab. This has been replicated in at least a dozen large randomized studies. Several recent developments have added complexities to what had appeared to be a clear biomarker and a consistent treatment algorithm.

Rosetta, Prometheus Settle Arbitration on MicroRNA Tests

Rosetta Genomics today said that it has settled an outstanding arbitration with Prometheurs Laboratories regarding commercialization rights to Rosetta’s microRNA-based tests.

Under the terms of the settlement, Rosetta has regained US commercial rights to its miRview mets, miRview squamous, and miRview meso tests. The Rehovot, Israel-based firm will pay Prometheus $3.1 million over the next 18 months, with an initial payment of $1.2 million due on Dec. 2.

MDxHealth Licenses Biomarkers for Bladder Cancer to Predictive Biosciences

MDxHealth SA, a leading molecular diagnostics company in the field of personalized cancer treatment, today announced that it has agreed to out-license certain DNA methylation biomarkers to Predictive Biosciences (Lexington, MA) for diagnostic applications in bladder cancer.